Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TVTX Stock Forecast 2026-2027
$42.60
Current Price
$3.96B
Market Cap
Buy 14
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to TVTX Price Targets
+40.8%
To High Target of $60.00
+27.9%
To Median Target of $54.50
+0.9%
To Low Target of $43.00
TVTX Price Momentum
-5.1%
1 Week Change
+47.1%
1 Month Change
+112.8%
1 Year Change
+11.5%
Year-to-Date Change
-12.4%
From 52W High of $48.61
+206.9%
From 52W Low of $13.88
📊 TOP ANALYST CALLS
Did TVTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Travere is one of their latest high-conviction picks.
Latest TVTX Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, TVTX has a bullish consensus with a median price target of $54.50 (ranging from $43.00 to $60.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $42.60, the median forecast implies a 27.9% upside. This outlook is supported by 14 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tyler Van Buren at TD Cowen, projecting a 40.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TVTX Analyst Ratings
14
Buy
1
Hold
0
Sell
TVTX Price Target Range
Low
$43.00
Average
$54.50
High
$60.00
Current: $42.60
Latest TVTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TVTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2026 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $50.00 |
| May 5, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $59.00 |
| May 5, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $57.00 |
| May 5, 2026 | TD Cowen | Tyler Van Buren | Buy | Maintains | $60.00 |
| May 5, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $55.00 |
| Apr 24, 2026 | Guggenheim | Vamil Divan | Buy | Maintains | $56.00 |
| Apr 14, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $47.00 |
| Apr 14, 2026 | Canaccord Genuity | Edward Nash | Buy | Maintains | $56.00 |
| Apr 14, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $53.00 |
| Apr 14, 2026 | Guggenheim | Vamil Divan | Buy | Maintains | $54.00 |
| Apr 14, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $44.00 |
| Mar 25, 2026 | JP Morgan | Anupam Rama | Overweight | Maintains | $41.00 |
| Feb 6, 2026 | Piper Sandler | Allison Bratzel | Neutral | Maintains | $38.00 |
| Nov 28, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $47.00 |
| Nov 4, 2025 | Piper Sandler | Allison Bratzel | Neutral | Maintains | $35.00 |
| Oct 31, 2025 | TD Cowen | Tyler Van Buren | Buy | Maintains | $40.00 |
| Sep 19, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $47.00 |
| Sep 12, 2025 | Stifel | Alex Thompson | Hold | Maintains | $25.00 |
| Sep 11, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $35.00 |
| Sep 10, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $47.00 |
Travere Therapeutics Inc. (TVTX) Competitors
The following stocks are similar to Travere based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Travere Therapeutics Inc. (TVTX) Financial Data
Travere Therapeutics Inc. has a market capitalization of $3.96B with a P/E ratio of -146.9x. The company generates $536.20M in trailing twelve-month revenue with a -4.0% profit margin.
Revenue growth is +55.6% quarter-over-quarter, while maintaining an operating margin of -29.0% and return on equity of -69.4%.
Valuation Metrics
Market Cap
$3.96B
Enterprise Value
$4.02B
P/E Ratio
-146.9x
PEG Ratio
9.9x
Price/Sales
7.4x
Growth & Margins
Revenue Growth (YoY)
+55.6%
Gross Margin
+79.0%
Operating Margin
-29.0%
Net Margin
-4.0%
EPS Growth
+55.6%
Financial Health
Cash/Price Ratio
+6.7%
Current Ratio
3.1x
Debt/Equity
331.9x
ROE
-69.4%
ROA
-6.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Travere Therapeutics Inc. (TVTX) Business Model
About Travere Therapeutics Inc.
What They Do
Develops therapies for rare diseases.
Business Model
Travere Therapeutics focuses on the development and commercialization of innovative therapies targeting rare diseases, specifically in nephrology and hepatology. The company generates revenue through the successful development and sale of its drug candidates that address unmet medical needs in small patient populations.
Additional Information
The company is notable for its commitment to scientific research and collaboration with healthcare professionals, which enhances its ability to innovate in niche medical fields. Travere's focus on diseases like focal segmental glomerulosclerosis and Alport syndrome positions it as a leader in the rare disease market, providing critical treatment options for patients with limited alternatives.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
497
CEO
Dr. Eric M. Dube Ph.D.
Country
United States
IPO Year
2003
Website
travere.comTravere Therapeutics Inc. (TVTX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
May 04, 2026
By Zacks Equity Research
Fundamental Analysis
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 04, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Travere Therapeutics (NASDAQ:TVTX) reported a profit for the first quarter, indicating positive financial performance.
Why It Matters
Travere Therapeutics turning a profit indicates strong financial health and potential for growth, likely boosting investor confidence and stock performance.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Travere Therapeutics, Inc. (TVTX) held its Q1 2026 earnings call, discussing financial performance and strategic updates. Further details and insights are available in the full transcript.
Why It Matters
Earnings calls provide insight into a company's financial health, strategic direction, and market performance, influencing investor sentiment and stock prices for Travere Therapeutics.
Source: Seeking Alpha
Market Sentiment:
Neutral
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
5 days ago
Quick Summary
Travere Therapeutics plans to offer $400 million in convertible senior notes due 2032, with a possible additional $60 million for over-allotments, subject to market conditions.
Why It Matters
Travere Therapeutics' offering of $400 million in convertible senior notes signals potential capital raise for growth, impacting liquidity and future equity structure, which may affect stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Travere Therapeutics priced an underwritten offering of $475 million in 0.50% convertible senior notes due 2032, increasing from an initial $400 million. Closing is set for May 11, 2026.
Why It Matters
Travere Therapeutics' increased convertible notes offering signals strong demand and could provide substantial capital for growth, affecting share valuation and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Travere Therapeutics will present at several investor conferences in 2026, including BofA on May 13, Jefferies on June 3, and Goldman Sachs on June 8.
Why It Matters
Upcoming presentations at major healthcare conferences can influence investor sentiment and stock performance by highlighting company strategies, pipeline developments, and potential partnerships.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Travere Therapeutics (Nasdaq: TVTX) reported Q1 2026 results, highlighting FILSPARI's approval for FSGS, strong demand in IgAN, and progress in the Phase 3 HARMONY study for pegtibatinase.
Why It Matters
Travere's strong Q1 results and FILSPARI's approval could drive revenue growth, while advancements in pegtibatinase signal ongoing innovation, impacting future stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About TVTX Stock
What is Travere Therapeutics Inc.'s (TVTX) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Travere Therapeutics Inc. (TVTX) has a median price target of $54.50. The highest price target is $60.00 and the lowest is $43.00.
Is TVTX stock a good investment in 2026?
According to current analyst ratings, TVTX has 14 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $42.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TVTX stock?
Wall Street analysts predict TVTX stock could reach $54.50 in the next 12 months. This represents a 27.9% increase from the current price of $42.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Travere Therapeutics Inc.'s business model?
Travere Therapeutics focuses on the development and commercialization of innovative therapies targeting rare diseases, specifically in nephrology and hepatology. The company generates revenue through the successful development and sale of its drug candidates that address unmet medical needs in small patient populations.
What is the highest forecasted price for TVTX Travere Therapeutics Inc.?
The highest price target for TVTX is $60.00 from Tyler Van Buren at TD Cowen, which represents a 40.8% increase from the current price of $42.60.
What is the lowest forecasted price for TVTX Travere Therapeutics Inc.?
The lowest price target for TVTX is $43.00 from at , which represents a 0.9% increase from the current price of $42.60.
What is the overall TVTX consensus from analysts for Travere Therapeutics Inc.?
The overall analyst consensus for TVTX is bullish. Out of 22 Wall Street analysts, 14 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $54.50.
How accurate are TVTX stock price projections?
Stock price projections, including those for Travere Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 5:15 AM UTC